VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac®

By | Press Releases, Sci-B-Vac®
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has completed a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to...
Read More